Expression of p16 gene has been reported in cancer cell lines and in certain malignant neoplasm. This gene encodes a protein that functions as a negative cell cycle regulator at G1-S checkpoint.
Expression of EGFR has been shown in human cancer and could serve as a target for diagnosis and therapy for malignancy. This study was conducted on a total of 14 benign breast tissues taken as control and 36 breast cancer patients [29 ductal, 7 Iobular] . RT-PCR and ELISA techniques were used for the detection of p16 and EGFR respectively. The results of this work revealed a significant increase of p16 expression was observed in benign breast tissue compared to malignant breast one p<0.001. Also, a significant increase of p16 expression was found in low grade, negative lymph node and in histological subtype ILC. The negative expression of p16 may be categorize the group of breast cancer patients [IDC] with a high grade. The mean level of EGFR expression was 37.3 +/- 3 and 363 +/- 72 fmol/mg protein in benign and malignant breast tissues respectively, which showed a significant increase in tumor tissues, p<0.001. EGFR level significantly correlated with lymph node positive tumors, and tumor size In conclusion: p16 and EGFR expression could be used as good criteria for characterizing the patients suffering from breast carcinomas. Farther work is strongly recommended for the possibility of using the previous biochemical parameters for diagnosis, prognosis and therapy for breast cancer
Saad M. ElGendy ,Saad M. ElGendy ,Motawa E. El houseini ,aAfaf Abdel Khalek ,Sanaa O. Abdallah ,Ahmed A. Sayed ,
Multiple tumor suppressor gene [mts1/p16]expression and epidermal growth factor receptor [egfr]level in breast carcinomas,
Egypt. J. Biochem. Mol. Biol. 2004;
17-32 Views : 0